Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.75 |
| ▸ | HSP90B1 | P14625 | 8/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122628 | 0.88 | HSP90AB1 (0.61) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL3124296 | 0.87 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3122454 | 0.87 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL14385051 | 0.86 | HSP90AB1 (0.81) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| Chloroderivative SCHEMBL3113758 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL3124508 | 0.85 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL3126623 | 0.84 | HSP90AB1 (0.78) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL3119599 | 0.83 | HSP90AB1 (0.55) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL3121963 | 0.83 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL3465421 | 0.82 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | HSP90AA1 809/4885HSP90AB1 239/4885HSP90B1 59/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | HSP90AA1 809/4885HSP90AB1 239/4885HSP90B1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.